FIG. 2.
Glial fibrillary acidic protein (GFAP) immunoreactivity dichotomizes human contusion–traumatic brain injury (TBI) specimens. (A-C) Two sections from the same patient, stained with hematoxylin and eosin (A) or immunolabeled for GFAP (B, C), with the latter shown at low (B) and high (C) magnification: Note absence of specific immunoreactivity for GFAP in the specimen on the left vs. specific labeling of stellate-shaped cells in the companion specimen on the right. (case #2, 11 days post-TBI).